GM1 gangliosidosis results from pathogenic variants in the GLB1 gene, which encodes lysosomal acid beta-galactosidase. The disorder follows an autosomal recessive inheritance pattern, meaning two disease-causing alleles—one inherited from each biological parent—are required for the condition to manifest. Deficient or absent beta-galactosidase activity leads to lysosomal accumulation of GM1 gangliosides, galactose-containing oligosaccharides, and keratan sulfate across multiple tissue types. The severity and rate of neurodegeneration correlate broadly with residual enzymatic activity, which in turn reflects the nature of the specific GLB1 mutations present. No environmental triggers have been identified; the etiology is entirely genetic.

Biochemical demonstration of markedly decreased beta-galactosidase activity in leukocytes, dried blood spots, or fibroblasts constitutes a primary diagnostic finding, present in 80–99% of affected individuals. Confirmation involves molecular analysis of the GLB1 gene to identify biallelic pathogenic variants. Brain MRI typically reveals characteristic signal abnormalities. Skeletal survey documents the extent of dysostosis multiplex. Ophthalmological examination identifies macular cherry-red spots in infantile cases. Urine oligosaccharide analysis may show elevated galactose-containing species. Newborn screening programs in some jurisdictions include lysosomal enzyme panels that can detect reduced beta-galactosidase activity. Prenatal diagnosis is feasible through enzymatic or molecular testing of chorionic villus or amniocyte samples.

No curative therapy has been approved specifically for GM1 gangliosidosis as of this packet. Multidisciplinary supportive care—addressing seizures, feeding difficulties, pulmonary secretions, spasticity, cardiac involvement, and skeletal complications—forms the foundation of documented management. Anti-seizure medications are used for seizure control, though complete control is rarely achieved. Gastrostomy tube placement is documented for persistent dysphagia. Surgical procedures are performed with awareness of documented anesthetic risks in lysosomal storage disorders, including potential atlantoaxial instability. Orphan-designated investigational agents include aloxistatin (DORPHAN SA), N-Acetyl-Leucine (IntraBio), and a biphenyl-substituted deoxynojirimycin derivative (Azafaros BV), alongside AAV-based gene therapy approaches under clinical investigation.

Prognosis varies substantially by subtype. Type 1 (infantile-onset) is characterized by rapid neurological deterioration beginning in the first months of life, with most affected individuals not surviving beyond early childhood. Type 2 presents a more variable trajectory; late-infantile cases typically progress to severe neurological disability within the first decade, while juvenile cases may have a slower course. Type 3 (adult/chronic) is associated with a milder, more prolonged course featuring dystonia and intellectual involvement without the severe visceral features seen in Type 1. Across all subtypes, neurological progression is generally irreversible with current supportive measures, and the primary causes of death include respiratory failure and aspiration complications.

Seven clinical trials are currently active or recruiting as documented in this packet. Notable investigations include a Phase 3 study evaluating oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms (NCT07054515, Azafaros B.V.), a Phase 1 study of intrathecal/intravenous gene transfer using PBGM01 in pediatric patients (NCT04713475, Gemma Biotherapeutics), and a Phase 1/2 intravenous AAV9 gene therapy trial expressing human beta-galactosidase (NCT03952637, NHGRI). A prenatal intravenous AAV9 gene transfer trial is not yet recruiting (NCT07479953). A natural history study at the University of Minnesota (NCT00668187) continues to characterize disease progression. The Cure GM1 Foundation maintains a patient registry supporting research coordination.